As a close analog of erlotinib, which is an approved drug for non-small cell lung cancer patients with EGFR mutations [61], AG-1478 has attracted great interest as a potential anticancer EGFR inhibitor that can be used to treat cancers with overexpressed EGFR, including non-small cell lung, pancreatic, breast and colorectal cancer, and was moved into a clinical trial for the treatment of glioblastoma multiforme (GBM) with constitutively active EGFR overexpression [62,63,64]. The gene discussed is EGFR; the disease is colorectal cancer.